CTX-009 + CTX-471
Phase 1/2Recruiting 0 watching 0 views this week💤 Quiet
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glioblastoma
Conditions
Glioblastoma
Trial Timeline
Apr 30, 2026 → Apr 30, 2031
NCT ID
NCT07392957About CTX-009 + CTX-471
CTX-009 + CTX-471 is a phase 1/2 stage product being developed by Compass Therapeutics for Glioblastoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07392957. Target conditions include Glioblastoma.
Hype Score Breakdown
Clinical
13
Activity
8
Company
5
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07392957 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Glioblastoma